1. HBW Insight
  2. >>Ingredients & Safety
  3. >>Cannabis/CBD

Funding For US FDA Work On Cannabinoids Regulatory Pathway Drives Progress Only So Far

 
• By Eileen Francis

FDA is conducting lab testing on CBD products with funding in its FY2021 appropriations, says senior agency advisor Sharon Mayl. Some work planned work in the area has been delayed by the agency's response to COVID-19.

The US Food and Drug Administration, says senior agency advisor Sharon Mayl, is making use of its fiscal year 2021 appropriation for developing a lawful pathway for using cannabidiol and other cannabinoids in non-drug products but realizes there’s little to show for the work so far.

“We are continuing to evaluate the data that we see on the safety of CBD itself

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cannabis/CBD

More from Ingredients & Safety

German Industry Urges ECHA To Reconsider ‘De Facto’ EU Ethanol Ban

 
• By David Ridley

Reclassifying ethanol as a carcinogenic, mutagenic, or reprotoxic substance - something the European Chemicals Agency seems likely to do in the near future - would be “tantamount to a de facto ban” with “fatal consequences” for medical care in Germany, says Pharma Deutschland in a joint paper with 13 other German healthcare industry associations.

AESGP: ‘No Evidence’ Of Antimicrobial Resistance With OTC Antifungals Or Antivirals

 
• By David Ridley

Two AESGP papers reviewing the evidence for AMR risk associated with a range of OTC antifungals and antivirals conclude there is litte to no risk associated with the responsible self-care use of such medicines.

AESGP Slams ‘Deeply Concerning And Discriminatory’ EU Wastewater Directive

 
• By David Ridley

“Protecting the environment is a shared responsibility. It is unfair to expect only two sectors to fund wastewater treatment modernization and operation,” argues AESGP director general Jurate Švarcaite.